MR CLEAN-NO IV:静脉溶栓后血管内治疗对比直接血管内治疗急性前循环大血管闭塞性卒中的随机试验方案
本研究为多中心随机开放标签盲法终点评价(PROBE设计)试验,拟纳入540例前循环大血管闭塞且符合静脉溶栓和血管内治疗条件的急性缺血性卒中患者,随机接受静脉阿替普酶(0.9 mg/kg)后血管内治疗或直接血管内治疗,主要结局为90天改良Rankin量表评分,旨在评估直接血管内治疗的优效性并探索其非劣效性。
要点
- 前循环大血管闭塞急性卒中患者,直接血管内治疗对比静脉溶栓后血管内治疗的疗效与安全性尚存临床均势。
- 主要结局为90天改良Rankin量表评分,采用有序回归校正预后变量估计治疗效应。
- 次要结局包括血管内治疗后eTICI再灌注分级和24小时NIHSS评分,安全性结局为 Heidelberg 标准评估的颅内出血。
核心结论
- MR CLEAN-NO IV试验旨在评估直接血管内治疗是否优于静脉阿替普酶后血管内治疗,并探索其非劣效性。
研究设计与样本
- 多中心随机开放标签盲法终点评价(PROBE设计)临床试验,计划纳入540例患者。
- 纳入标准:年龄≥18岁,卒中前mRS<3,CT血管造影/MR血管造影证实前循环大血管闭塞,且同时符合静脉溶栓和血管内治疗条件。
- 随机1:1接受静脉阿替普酶(0.9 mg/kg)后血管内治疗或直接血管内治疗。
关键数值与推荐
- 主要结局为90天改良Rankin量表评分,采用有序回归校正预后变量估计治疗效应。
- 次要结局包括血管内治疗后eTICI量表再灌注分级和24小时NIHSS评分。
- 安全性结局包括按Heidelberg标准评估的颅内出血。
- 主要目标为评估直接血管内治疗的优效性,次要探索其对比静脉溶栓后血管内治疗的非劣效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular treatment (EVT) has greatly improved the prognosis of acute ischemic stroke (AIS) patients with a proximal intracranial large vessel occlusion (LVO) of the anterior circulation. Currently, there is clinical equipoise concerning the added benefit of intravenous alteplase administration (IVT) prior to EVT. The aim of this study is to assess the efficacy and safety of omitting IVT before EVT in patients with AIS caused by an anterior circulation LVO. METHODS: MR CLEAN-NO IV is a multicenter randomized open-label clinical trial with blinded outcome assessment (PROBE design). Patients ≥ 18 years of age with a pre-stroke mRS < 3 with an LVO confirmed on CT angiography/MR angiography eligible for both IVT and EVT are randomized to receive either IVT (0.9 mg/kg) followed by EVT, or direct EVT in a 1:1 ratio. The primary objective is to assess superiority of direct EVT. Secondarily, non-inferiority of direct EVT compared to IVT before EVT will be explored. The primary outcome is the score on the modified Rankin Scale at 90 days. Ordinal regression with adjustment for prognostic variables will be used to estimate treatment effect. Secondary outcomes include reperfusion graded with the eTICI scale after EVT and stroke severity (National Institutes of Health Stroke Scale) at 24 h. Safety outcomes include intracranial hemorrhages scored according to the Heidelberg criteria. A total of 540 patients will be included. DISCUSSION: IVT prior to EVT might facilitate early reperfusion before EVT or improved reperfusion rates during EVT. Conversely, among other potential adverse effects, the increased risk of bleeding could nullify the beneficial effects of IVT. MR CLEAN-NO IV will provide insight into whether IVT is still of added value in patients eligible for EVT. TRIAL REGISTRATION: www.isrctn.com : ISRCTN80619088 . Registered on 31 October 2017.
引用
- Treurniet KM, LeCouffe NE, Kappelhof M, et al. MR CLEAN-NO IV: intravenous treatment followed by endovascular treatment versus direct endovascular treatment for acute ischemic stroke caused by a proximal intracranial occlusion-study protocol for a randomized clinical trial. Trials. 2021. PMID: 33588908. doi:10.1186/s13063-021-05063-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。